Original Article
A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery Disease
N Engl J Med 2009; 361:2538-2547December 24, 2009DOI: 10.1056/NEJMoa0805299
- Abstract
Background
In most patients with stable coronary artery disease, plasma cardiac troponin T levels are below the limit of detection for the conventional assay. The distribution and determinants of very low circulating troponin T levels, as well as their association with cardiovascular events, in such patients are unknown.
Methods
We used a new, high-sensitivity assay to determine the concentration of cardiac troponin T in plasma samples from 3679 patients with stable coronary artery disease and preserved left ventricular function. Results of the assay were analyzed in relation to the incidence of cardiovascular events during a median follow-up period of 5.2 years.
Results
With the highly sensitive assay, concentrations of cardiac troponin T were at or above the limit of detection (0.001 μg per liter) in 3593 patients (97.7%) and at or above the 99th percentile for apparently healthy subjects (0.0133 μg per liter) in 407 patients (11.1%). After adjustment for other independent prognostic indicators, there was a strong and graded increase in the cumulative incidence of cardiovascular death (adjusted hazard ratio per unit increase in the natural logarithm of the troponin T level, 2.09; 95% confidence interval [CI], 1.60 to 2.74; P<0.001) and of heart failure (adjusted hazard ratio, 2.20; 95% CI, 1.66 to 2.90; P<0.001) in this study group. Increased risk associated with higher levels of troponin T was evident well below the limit of detection of conventional cardiac troponin T assays and below the 99th percentile of values in a healthy population. There was no association between troponin T levels as measured with the highly sensitive assay and the incidence of myocardial infarction (adjusted hazard ratio, 1.16; 95% CI, 0.97 to 1.40; P=0.11).
Conclusions
After adjustment for other independent prognostic indicators, cardiac troponin T concentrations as measured with a highly sensitive assay were significantly associated with the incidence of cardiovascular death and heart failure but not with myocardial infarction in patients with stable coronary artery disease.
Media in This Article
Figure 1
Distribution of High-Sensitivity Cardiac Troponin T in Patients with Stable Coronary Artery Disease (CAD) and in Apparently Healthy Blood Donors.Figure 2
Incidence of Cardiovascular Death According to Quartile of High-Sensitivity Cardiac Troponin T Level.Article Activity
- Article
Cardiac troponins T and I are components of the contractile apparatus of cardiomyocytes and are the preferred biochemical markers of myocardial necrosis in patients with suspected acute coronary syndromes.1 Among such patients, a strong association between elevated troponin levels and recurrent coronary ischemic events has been firmly established.2-4
It has been shown that even very small elevations in troponins are associated with an increased risk of an adverse outcome in patients with acute coronary syndromes.5 Moreover, among men clinically free of cardiovascular disease, as well as in patients with recent acute coronary syndromes, levels of cardiac troponin greater than 0.01 μg per liter have been associated with increased mortality.6,7 Thus, it seems plausible that cardiac troponin levels below the conventional limits of detection may further discriminate between subjects at high risk and those at low risk for future cardiovascular events.
A highly sensitive assay for cardiac troponin T has recently been developed, permitting measurement of concentrations that are lower by a factor of 10 than those measurable with conventional assays. We hypothesized that with the highly sensitive assay, cardiac troponin T would be detectable in patients who had stable coronary artery disease without heart failure or left ventricular systolic dysfunction and that these levels would be associated with the risk of future cardiovascular events.
Methods
Patients
This substudy involved patients who had been included in the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial (ClinicalTrials.gov number, NCT00000558). The design, entry criteria, and main results of this trial have been described previously.8 In brief, from November 1996 through June 2000, a total of 8290 patients with stable coronary artery disease and preserved left ventricular systolic function were randomly assigned to receive either the angiotensin-converting–enzyme inhibitor trandolapril or placebo. All the participants were free of heart failure at baseline, and none had been hospitalized for unstable angina within the 3 months preceding trial entry. (For details about the inclusion and exclusion criteria, see Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.) Patients were followed every 6 months until December 2003, for a median of 5.2 years. The PEACE trial was sponsored by the National Heart, Lung, and Blood Institute (NHLBI) with support from Knoll Pharmaceuticals and Abbott Laboratories. It was conducted after approval by ethics committees from all participating sites, and patients provided written informed consent.
All participants from the United States and Canada were eligible for biospecimen collection, and approximately half the participants agreed to provide a baseline blood sample. All patients who had baseline EDTA-treated plasma samples for measurement of troponin T were included in this substudy.
Biomarker Substudy
This biomarker study was designed by the first author and supported by Roche Diagnostics. Clinical data were collected by the clinical sites; biomarkers were assayed by two of the authors in 2007. The data were held and analyzed by the clinical and statistical coordinating center at George Washington University, Rockville, Maryland. The first author wrote the first draft of the manuscript, which was revised by all the authors. The NHLBI project officers (but not Knoll Pharmaceuticals, Abbott Laboratories, or Roche Diagnostics) played a role in the study design; collection, analysis, and interpretation of data; the writing of the report; and the decision to submit the manuscript for publication. The first author and the coordinating center take responsibility for the accuracy and completeness of the data presented.
Before randomization, EDTA-treated plasma samples were obtained from trial participants and centrifuged at room temperature. The plasma component was aspirated and frozen at −20°C at individual centers. Within 3 months after collection, plasma samples were shipped on dry ice to the central laboratory for storage at or below −70°C, pending analysis.
Biochemical Analysis
Levels of cardiac troponin T were determined by means of an autoanalyzer (cobas e 411, Roche Diagnostics). The lower limit of detection of the precommercial highly sensitive assay was 0.001 μg per liter.9 The value at the 99th percentile in a sample of 1338 apparently healthy blood donors was 0.0133 μg per liter (Roche Diagnostics, data on file). The detection limit of the older Roche troponin T assay (the fourth-generation Elecsys troponin T assay) is 0.01 μg per liter; according to the manufacturer, this corresponds to a value of 0.03 μg per liter with the new assay. (Details regarding the characteristics of the newer assay are provided in the Supplementary Appendix.)
N-terminal pro–brain natriuretic peptide (NT-proBNP) concentrations were determined with an electrochemiluminescence immunoassay on a Modular platform (Roche Diagnostics).10 C-reactive protein (CRP) measurements were performed with the highly sensitive CRP-Latex (II) immunoturbidimetric assay (Denka Seiken) on a Hitachi 911 immunoanalyzer (Roche Diagnostics).11 The glomerular filtration rate was estimated with the use of the four-variable Modification of Diet in Renal Disease (MDRD) equation.12 All biochemical testing was performed by study personnel who were unaware of the clinical outcomes and treatment assignments in the main study.
Outcomes
The outcomes examined in this analysis included cardiovascular death, fatal and nonfatal heart failure, and fatal and nonfatal acute myocardial infarction. All events were confirmed by a review of medical records. Cardiovascular death and fatal and nonfatal myocardial infarction were prespecified end points of the PEACE trial that underwent blinded review by an outcomes committee. Heart failure was classified by centrally trained local staff and confirmed by staff at the coordinating center through a review of hospital records. For an event to be classified as nonfatal heart failure, hospitalization with a primary cause of heart failure was required. All clinical events were classified before biomarkers were measured.
Statistical Analysis
Baseline characteristics are reported as percentages for categorical variables and means ±SD for continuous variables. We used analysis-of-variance and chi-square tests to test for differences in continuous and categorical baseline characteristics between sex-specific quartiles of cardiac troponin T levels. The overall F-test is reported for the analysis-of-variance models. Pearson's correlation was used to describe the association between the natural logarithm of the troponin T level and quantitative risk factors (after logarithmic transformation, when appropriate).
Cox proportional-hazards models were used to examine the association between troponin T levels as determined by the highly sensitive assay and outcome events; data were censored at the time of the last visit. In these models, the troponin T level was examined both as a continuous variable (after logarithmic transformation) and as a categorical variable by sex-specific quartiles. Cox models sequentially added treatment group, age, sex, smoking status, body-mass index, ejection fraction, glomerular filtration rate, total cholesterol level, presence or absence of a history of various cardiovascular events or conditions (hypertension, myocardial infarction, diabetes mellitus, stroke, percutaneous coronary intervention, or coronary-artery bypass grafting), and medications (beta-blockers, lipid-lowering drugs, diuretics, and aspirin or antiplatelet drugs). The collinearity index was used to check for linear combinations among covariates.13
The final model was adjusted for treatment assignment and for baseline variables that are significantly associated with cardiovascular death (age, sex, and current smoking status), as well as for CRP values and NT-proBNP levels. We tested for an interaction between treatment assignment and the effect of troponin T level on the outcome by adding interaction terms in the models. Nelson–Aalen curves were generated to show the cumulative incidence of cardiovascular death for each quartile of troponin T.
Estimates of the C statistic for the Cox regression models were calculated with the method described by Pencina and D'Agostino.14 Covariate-adjusted receiver-operating-characteristic plots were also generated for models both with and without high-sensitivity cardiac troponin T. The increased discriminative value of the troponin T level was examined by using the integrated discrimination improvement (IDI) measure15 to estimate the change in the predictive survival probabilities for cardiovascular death. Discrimination slopes were compared between models with and without the troponin T data. We assessed model calibration by comparing predicted probabilities with observed probabilities.16 Residual analysis was used to assess model fit.
A P value of less than 0.05 was considered to indicate statistical significance, and all tests were two-sided. No adjustment for multiple comparisons was performed. The SAS analysis system, version 9.1, was used for all analyses (SAS Institute).
Results
Baseline Characteristics of the Patients
Baseline troponin T measurements were available from 3679 patients at 187 clinical sites. Characteristics of the patients included in the main PEACE study and in the biomarker substudy are summarized in Table 2 in the Supplementary Appendix. There were no clinically relevant differences between patients included in the substudy and those not included in it. The mean (±SD) age of patients in the substudy was 63.6±8.2 years, 18.9% were women, and 91.6% were white (Table 1Table 1
Characteristics of the Patients at Baseline.). All patients had stable coronary artery disease, and 56.3% had a history of myocardial infarction, 45.6% of percutaneous coronary intervention, and 35.8% of coronary-artery bypass grafting.Distribution and Determinants of Very Low Levels of Troponin T
Concentrations of troponin T as measured with the highly sensitive assay were at or above the limit of detection (0.001 μg per liter) in 3593 patients (97.7%) and equal to or greater than the 99th percentile value for apparently healthy subjects (0.0133 μg per liter) in 407 patients (11.1%). The distribution of troponin T concentrations in patients with stable coronary artery disease and in apparently healthy blood donors is shown in Figure 1Figure 1
Distribution of High-Sensitivity Cardiac Troponin T in Patients with Stable Coronary Artery Disease (CAD) and in Apparently Healthy Blood Donors.. Troponin T levels were higher in men than in women (median, 0.0063 vs. 0.0046 μg per liter; P<0.001). Characteristics of the patients according to sex-specific quartiles of troponin T values are shown in Table 1. Levels of troponin T were positively associated with several conventional risk factors.Troponin T and Cardiovascular Events
Cardiovascular Deaths
During follow-up, there were 125 cardiovascular deaths in the biomarker substudy cohort. In the univariate model, the cumulative incidence of cardiovascular deaths was significantly associated with the cardiac troponin T level (hazard ratio per unit increase in the natural logarithm of the value for troponin T, 2.78; 95% confidence interval [CI], 2.24 to 3.45; P<0.001) (Table 2Table 2
Association between High-Sensitivity Cardiac Troponin T as a Continuous Variable and Cardiovascular Outcomes.). After adjustment for age, sex, smoking status, and high-sensitivity CRP level by using the multivariate model 1, the association remained strong (hazard ratio, 2.39; 95% CI, 1.85 to 3.09; P<0.001). The addition of NT-proBNP as a covariate in the multivariate model modestly attenuated the association, but the relation still remained highly significant (hazard ratio, 2.09; 95% CI, 1.60 to 2.74; P<0.001).The risk of cardiovascular death associated with increasing quartiles of troponin T was also strong and graded (P<0.001 for trend) (Figure 2Figure 2
Incidence of Cardiovascular Death According to Quartile of High-Sensitivity Cardiac Troponin T Level.). This trend remained significant (P<0.001) after multivariate adjustment (Table 3 in the Supplementary Appendix). Moreover, when the first quartile was used as the reference category, the adjusted association with risk was significant for both the third and fourth quartiles of troponin T (Fig. 1 in the Supplementary Appendix). When the first decile was used as the reference, the hazard ratio point estimates were only slightly increased from the second to the fifth decile, with an apparent threshold effect corresponding to the sixth decile (Fig. 2 in the Supplementary Appendix). Since only 407 patients had levels above the 99th percentile for apparently healthy subjects (0.0133 μg per liter — i.e., within the ninth decile), the troponin T levels determined by the highly sensitive assay appear to provide independent prognostic information below this limit.Of the 3679 participants, 3630 had troponin T levels that would be expected to be undetectable by the conventional assay (i.e., <0.01 μg per liter, which corresponds to <0.03 μg per liter with the new assay). In this subgroup, 117 cardiovascular deaths occurred. The risk estimate for these 3630 patients was similar to that for the entire cohort (hazard ratio, 2.14; 95% CI, 1.52 to 3.04; P<0.001), suggesting that the newer troponin T assay provides powerful prognostic information in patients who would have undetectable levels with the conventional assay.
Heart Failure
During follow-up there were 104 first hospitalizations for fatal or nonfatal heart failure. In unadjusted analyses, the incidence of heart failure increased with increasing levels of troponin T (Table 2). After adjustment, the association remained highly significant (hazard ratio, 2.20; 95% CI, 1.66 to 2.90; P<0.001). The risk of heart failure associated with increasing quartiles of troponin T levels was also strong and graded in both univariate and multivariate analyses (P<0.001 for trend) (Table 3 in the Supplementary Appendix).
Cardiovascular Deaths Not Due to Heart Failure
There were 112 cardiovascular deaths classified as not being due to heart failure during follow-up. In an unadjusted analysis, the cumulative incidence of this end point was significantly associated with troponin T (Table 2). After adjustment, the association was modestly attenuated but remained highly significant (hazard ratio, 1.95; 95% CI, 1.46 to 2.61; P<0.001). The risk of this outcome in association with increasing quartiles of troponin T levels was also strong and graded above the second quartile (P<0.001 for trend) (Table 3 in the Supplementary Appendix).
Myocardial Infarction
During follow-up, there were 233 fatal or nonfatal acute myocardial infarctions. In an unadjusted analysis, there was a weak but significant increase in the cumulative incidence of myocardial infarction with increasing troponin T levels (Table 2). After adjustment, this association was no longer significant (hazard ratio, 1.16; 95% CI, 0.97 to 1.40; P=0.11). Likewise, an unadjusted analysis showed a weak association between the risk of myocardial infarction and increasing quartiles of troponin T that was of borderline significance; after adjustment for potentially confounding variables, this association was no longer significant (P=0.54) (Table 3 in the Supplementary Appendix).
Discrimination, Reclassification, and Calibration
For the end point of cardiovascular death, the C statistic of the sequential model that included high-sensitivity CRP was 0.70. Adding troponin T to this model increased the C statistic to 0.75 (P<0.001) (Figure 3AFigure 3
Covariate-Adjusted Receiver-Operating-Characteristic Plots for the Use of High-Sensitivity Cardiac Troponin T to Predict the Risk of Cardiovascular Death.). The C statistic of the sequential model that included high-sensitivity CRP and NT-proBNP was 0.74. Adding troponin T to this model modestly but significantly increased the C statistic, to 0.76 (P=0.007) (Figure 3B).The IDI for the end point of cardiovascular death was calculated. Inclusion of troponin T in the final sequential model that also included high-sensitivity CRP resulted in a significant improvement in performance of the model (IDI, 0.018; P<0.001). This was also true for the model that included both high-sensitivity CRP and NT-proBNP (IDI, 0.014; P<0.001). Calibration of the models with and without troponin T showed no evidence of lack of fit.
Discussion
This study shows that very low circulating levels of cardiac troponin T are detectable in the great majority of patients who have stable coronary artery disease with preserved left ventricular function, that multiple conventional risk factors are associated with higher troponin T concentrations in this population, and that very low circulating levels of troponin T have a graded relationship with the incidence of cardiovascular death and heart failure in such patients. Conversely, the association between troponin T concentrations and incident myocardial infarction was not significant after adjustment for potential confounding factors. This finding stands in stark contrast to observations in patients with acute coronary syndromes, in whom troponins are considered biomarkers of acute cardiovascular injury due to plaque rupture and intracoronary thrombosis17 and more accurately predict recurrent myocardial infarction than they do death or heart-failure events.18
With the use of conventional assays, the prevalence of detectable concentrations of cardiac troponin T in the general population is approximately 0.7%.19 Detectable troponin T levels in such a population are typically associated with established cardiovascular disease, such as left ventricular hypertrophy or dysfunction, or with high-risk conditions such as kidney disease or diabetes. The mechanisms responsible for the release of very low levels of cardiac troponin T in patients with stable coronary artery disease could include transient, clinically silent ischemic episodes and small-vessel occlusions; inflammatory processes; cardiomyocyte apoptosis20; reduced renal clearance; and increased myocardial strain due to pressure or volume overload. However, the remarkably high prevalence of detectable troponin in this low-risk cohort raises the possibility that some troponin may circulate under normal circumstances in human plasma. Data from population studies will be needed to confirm this hypothesis, and the source of the release of cardiac troponin T will need to be studied in experimental models.
In a previous study, the prognostic value of the highly sensitive cardiac troponin T assay was investigated in patients with chronic symptomatic heart failure and systolic dysfunction.9 A strong and graded association with mortality and the risk of heart failure was observed, even after adjustment for NT-proBNP. The current study extends these findings to a lower-risk population with stable coronary artery disease and no evidence of heart failure or left ventricular systolic dysfunction.
The observations that troponin T was detectable in almost all our patients and that it provided strong prognostic information independently of conventional risk factors and other contemporary biomarkers, such as NT-proBNP and high-sensitivity CRP, suggest that assessment of low-level chronic myocardial injury may represent a new means by which clinicians can stratify risk among patients with stable coronary artery disease and preserved left ventricular function. Unresolved questions that need to be addressed include whether serial testing would enhance the prognostic value of the assay and whether minor changes in very low levels are stronger predictors of events than are absolute values. Moreover, before routine testing is considered, the therapeutic implications will need to be fully explored. Certain negative implications merit consideration as well. As more sensitive assays for troponins are introduced clinically, the specificity of low-level troponin elevation for acute myocardial injury in patients with acute chest pain syndromes may be reduced.
Limitations of our study include the selection of patients participating in a clinical trial (who may not be fully representative of patients in the general population), the use of a noncommercially available prototype assay that may not be perfectly calibrated with existing conventional assays, and the fact that heart-failure events were not a component of the prespecified primary outcome in the original trial design. In addition, we cannot rule out the presence of asymptomatic cardiovascular disease in the group of apparently healthy blood donors whose troponin T values were used for comparison, although anyone who was receiving medication for cardiovascular disease was excluded from this group. Accordingly, we cannot rule out the possibility of a lower 99th percentile value with the use of a more rigorous screening procedure. Moreover, the PEACE study population was predominantly white, and more than 80% of the patients were men. Therefore, extrapolation of our results to other demographic groups should be done with caution.
In conclusion, very low levels of troponin T were detectable in the great majority of patients with stable coronary artery disease. Levels well below the limit of detection of previous assays and below the 99th percentile in apparently healthy blood donors were strongly associated with the incidence of cardiovascular death and heart failure. In contrast, troponin T levels were not independently associated with the incidence of myocardial infarction.
Dr. Omland reports receiving lecture fees and grant support from Abbott Laboratories and Roche Diagnostics; Dr. de Lemos, grant support and consulting fees from Biosite/Inverness and Roche Diagnostics, lecture fees from Roche Diagnostics, and consulting fees from Tethys Bioscience and Johnson & Johnson; Dr. Sabatine, grant support from Roche Diagnostics, Singulex, diaDexus, and Ortho Clinical Diagnostics and consulting fees from Singulex; Drs. Christophi, Rice, and Jablonski, grant support from Knoll Pharmaceuticals and Abbott Laboratories; Dr. Gersh, receiving consulting fees from Amorcyte, AstraZeneca, Bristol-Myers Squibb, Boston Scientific, and Abbott Laboratories, and having equity ownership in CV Therapeutics; Dr. Rouleau, receiving consulting fees from Novartis and NicOx, lecture fees from Pfizer and Novartis, and grant support from Scios; and Dr. Pfeffer, receiving grant support from Abbott, Amgen, Atherogenics, Novartis, and Sanofi-Aventis, lecture fees from Bristol-Myers Squibb and Pfizer, and consulting fees from AstraZeneca, BMS, Genzyme, Novartis, and Pfizer and being listed as a coinventor on patents regarding the use of inhibition of the renin–angiotensin system that are licensed to Abbott and Novartis. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0805299) was published on November 25, 2009, at NEJM.org.
We thank the PEACE investigators, research coordinators, and committee members and Ms. Nina Samuelsen.
Source Information
From the Division of Medicine (T.O.) and the Center of Laboratory Medicine (S.T.), Akershus University Hospital, Lørenskog, Norway; the Faculty Division Akershus University Hospital and the Center for Heart Failure Research, University of Oslo, Oslo (T.O.); the Department of Medicine, University of Texas Southwestern Medical Center, Dallas (J.A.L.); the Department of Medicine, Harvard Medical School, and the Cardiovascular Division, Brigham and Women's Hospital — both in Boston (M.S.S., M.A.P., E.B.); the Biostatistics Center, George Washington University, Rockville, MD (C.A.C., M.M.R., K.A.J.); National Heart, Lung, and Blood Institute, Bethesda, MD (M.J.D.); the Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN (B.J.G.); and Montreal Heart Institute, and Faculty of Medicine, University of Montreal — both in Montreal (J.L.R.).
Address reprint requests to Dr. Omland at the Division of Medicine, Akershus University Hospital, NO-1478 Lørenskog, Norway, or at torbjorn.omland@medisin.uio.no.
- References
References
1
Gupta S ,de Lemos JA . Use and misuse of cardiac troponins in clinical practice. Prog Cardiovasc Dis 2007;50:151-165
CrossRef | Web of Science | Medline2
Hamm CW ,Ravkilde J ,Gerhardt W , et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992;327:146-150
Free Full Text | Web of Science | Medline3
Lindahl B ,Toss H ,Siegbahn A ,Venge P ,Wallentin L . Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-1147
Free Full Text | Web of Science | Medline4
Antman EM ,Tanasijevic MJ ,Thompson B , et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-1349
Free Full Text | Web of Science | Medline5
James S ,Armstrong P ,Califf R , et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med 2003;115:178-184
CrossRef | Web of Science | Medline6
Zethelius B ,Johnston N ,Venge P . Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006;113:1071-1078
CrossRef | Web of Science | Medline7
Eggers KM ,Lagerqvist B ,Venge P ,Wallentin L ,Lindahl B . Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. Circulation 2007;116:1907-1914
CrossRef | Web of Science | Medline8
The PEACE Trial Investigators
Free Full Text | Web of Science | Medline9
Latini R ,Masson S ,Anand IS , et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-1249
CrossRef | Web of Science | Medline10
Omland T ,Sabatine MS ,Jablonski KA , et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007;50:205-214
CrossRef | Web of Science | Medline11
Roberts WL ,Moulton L ,Law TC , et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2001;47:418-425[Erratum, Clin Chem 2001;47:980.]
Web of Science | Medline12
Levey AS ,Bosch JP ,Lewis JB ,Greene T ,Rogers N ,Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
CrossRef | Web of Science | Medline13
Belsley DA, Kuh E, Welsch RE. Regression diagnostics: identifying influential data and sources of collinearity. New York: John Wiley, 1980.
14
Pencina MJ ,D'Agostino RB . Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109-2123
CrossRef | Web of Science | Medline15
Pencina MJ ,D'Agostino RB ,D'Agostino RB Jr ,Vasan RS . Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172
CrossRef | Web of Science | Medline16
Gronnesby JK ,Borgan O . A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal 1996;2:315-328
CrossRef | Medline17
Wong GC ,Morrow DA ,Murphy S , et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy: Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002;106:202-207
CrossRef | Web of Science | Medline18
Lindahl B ,Diderholm E ,Lagerqvist B ,Venge P ,Wallentin L . Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001;38:979-986
CrossRef | Web of Science | Medline19
Wallace TW ,Abdullah SM ,Drazner MH , et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006;113:1958-1965
CrossRef | Web of Science | Medline20
Olivetti G ,Abbi R ,Quaini F , et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-1141
Free Full Text | Web of Science | Medline
- Citing Articles (156)
Citing Articles
1
Anna Axelsson, Martin Huth Ruwald, Morten Dalsgaard, Kasper Rossing, Rolf Steffensen, Kasper Iversen. (2013) Serial measurements of high-sensitivity cardiac troponin T after exercise stress test in stable coronary artery disease. Biomarkers 18:4, 304-309
2
Philipp Bahrmann, Michael Christ, Anke Bahrmann, Harald Rittger, Hans Jürgen Heppner, Stephan Achenbach, Thomas Bertsch, Cornel C. Sieber. (2013) A 3-Hour Diagnostic Algorithm for Non-ST-Elevation Myocardial Infarction Using High-Sensitivity Cardiac Troponin T in Unselected Older Patients Presenting to the Emergency Department. Journal of the American Medical Directors Association 14:6, 409-416
3
Camille Chenevier-Gobeaux, Christophe Meune, Yonathan Freund, Karim Wahbi, Yann-Erick Claessens, Benoit Doumenc, Stéphane Zuily, Bruno Riou, Patrick Ray. (2013) Influence of Age and Renal Function on High-Sensitivity Cardiac Troponin T Diagnostic Accuracy for the Diagnosis of Acute Myocardial Infarction. The American Journal of Cardiology 111:12, 1701-1707
4
Maria Giulia Marini, Maria Teresa Cardillo, Annalisa Caroli, Chiara Sonnino, Luigi M. Biasucci. (2013) Increasing specificity of high-sensitivity troponin: New approaches and perspectives in the diagnosis of acute coronary syndromes. Journal of Cardiology
5
Yasser E. Nassef, Manal A. Hamed, Hanan F. Aly. (2013) Inflammatory Cytokines, Apoptotic, Tissue Injury and Remodeling Biomarkers in Children with Congenital Heart Disease. Indian Journal of Clinical Biochemistry
6
Z. Hijazi, J. Oldgren, A. Siegbahn, C. B. Granger, L. Wallentin. (2013) Biomarkers in atrial fibrillation: a clinical review. European Heart Journal 34:20, 1475-1480
7
Kai M. Eggers, Per Venge, Bertil Lindahl, Lars Lind. (2013) Cardiac Troponin I Levels Measured With a High-Sensitive Assay Increase Over Time and Are Strong Predictors of Mortality in an Elderly Population. Journal of the American College of Cardiology 61:18, 1906-1913
8
Merel E. Hellemons, Hiddo J. Lambers Heerspink, Ron T. Gansevoort, Dick de Zeeuw, Stephan J.L. Bakker. (2013) High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case–control study with confirmation in diabetes. Journal of Hypertension 31:4, 805-812
9
Bo-Bae Kim, Yo-Han Ku, Jung-Yeon Han, Jung-Min Ha, Geon Park, Dong-Hyun Choi, Heesang Song. (2013) Relation of Triiodothyronine to Subclinical Myocardial Injury in Patients With Chest Pain. The American Journal of Cardiology 111:8, 1087-1091
10
Joseph L Blackshear, Thomas G Brott. (2013) Ascertainment of any and all neurologic and myocardial damage in carotid revascularization: the key to optimization?. Expert Review of Cardiovascular Therapy 11:4, 469-484
11
Christian Erbel, Rukiye Taskin, Andreas Doesch, Thomas J Dengler, Susanne Wangler, Mohammadreza Akhavanpoor, Arjang Ruhparwar, Evangelos Giannitsis, Hugo A. Katus, Christian A. Gleissner. (2013) High-sensitive Troponin T measurements early after heart transplantation predict short- and long-term survival. Transplant International 26:3, 267-272
12
M. Karakas, W. Koenig. (2013) Improved peri-operative risk stratification in non-cardiac surgery: going beyond established clinical scores. European Heart Journal 34:11, 796-798
13
M. Weber, A. Luchner, S. Manfred, C. Mueller, C. Liebetrau, A. Schlitt, S. Apostolovic, R. Jankovic, D. Bankovic, M. Jovic, V. Mitrovic, H. Nef, H. Mollmann, C. W. Hamm. (2013) Incremental value of high-sensitive troponin T in addition to the revised cardiac index for peri-operative risk stratification in non-cardiac surgery. European Heart Journal 34:11, 853-862
14
Torbjørn Omland, Marc A. Pfeffer, Scott D. Solomon, James A. de Lemos, Helge Røsjø, Jūratė Šaltytė Benth, Aldo Maggioni, Michael J. Domanski, Jean L. Rouleau, Marc S. Sabatine, Eugene Braunwald. (2013) Prognostic Value of Cardiac Troponin I Measured With a Highly Sensitive Assay in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology 61:12, 1240-1249
15
S. Masson, R. Latini, G. F. Mureddu, N. Agabiti, M. Miceli, G. Cesaroni, F. Forastiere, U.-H. Wienhues-Thelen, D. Block, C. Zaugg, T. Vago, A. Boccanelli, . (2013) High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac phenotype in a general population of elderly individuals. Journal of Internal Medicine 273:3, 306-317
16
Toshinobu Saito, Yukihiro Hojo, Masahiro Hirose, Tomokazu Ikemoto, Takaaki Katsuki, Kazuomi Kario. (2013) High-sensitivity troponin T is a prognostic marker for patients with aortic stenosis after valve replacement surgery. Journal of Cardiology
17
Satoshi Hoshide, Motoki Fukutomi, Kazuo Eguchi, Tomonori Watanabe, Tomoyuki Kabutoya, Kazuomi Kario. (2013) Change in High-Sensitive Cardiac Troponin T on Hypertensive Treatment. Clinical and Experimental Hypertension 35:1, 40-44
18
Richard L. Popp. (2013) Troponin. Journal of the American College of Cardiology 61:6, 611-614
19
Kashif Waqar Faiz, Bente Thommessen, Gunnar Einvik, Torbjørn Omland, Ole Morten Rønning. (2013) Prognostic Value of High-sensitivity Cardiac Troponin T in Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases
20
Eugene Braunwald. (2013) Heart Failure. JACC: Heart Failure 1:1, 1-20
21
Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Maarten L. Simoons, Bernard R. Chaitman, Harvey D. White, Kristian Thygesen, Joseph S. Alpert, Harvey D. White, Allan S. Jaffe, Hugo A. Katus, Fred S. Apple, Bertil Lindahl, David A. Morrow, Bernard R. Chaitman, Peter M. Clemmensen, Per Johanson, Hanoch Hod, Richard Underwood, Jeroen J. Bax, Robert O. Bonow, Fausto Pinto, Raymond J. Gibbons, Keith A. Fox, Dan Atar, L. Kristin Newby, Marcello Galvani, Christian W. Hamm, Barry F. Uretsky, P. Gabriel Steg, William Wijns, Jean-Pierre Bassand, Phillippe Menasché, Jan Ravkilde, E. Magnus Ohman, Elliott M. Antman, Lars C. Wallentin, Paul W. Armstrong, Maarten L. Simoons, James L. Januzzi, Markku S. Nieminen, Mihai Gheorghiade, Gerasimos Filippatos, Russell V. Luepker, Stephen P. Fortmann, Wayne D. Rosamond, Dan Levy, David Wood, Sidney C. Smith, Dayi Hu, José Luis López-Sendón, Rose Marie Robertson, Douglas Weaver, Michal Tendera, Alfred A. Bove, Alexander N. Parkhomenko, Elena J. Vasilieva, Shanti Mendis, Jeroen J. Bax, Helmut Baumgartner, Claudio Ceconi, Veronica Dean, Christi Deaton, Robert Fagard, Christian Funck-Brentano, David Hasdai, Arno Hoes, Paulus Kirchhof, Juhani Knuuti, Philippe Kolh, Theresa McDonagh, Cyril Moulin, Bogdan A. Popescu, Željko Reiner, Udo Sechtem, Per Anton Sirnes, Michal Tendera, Adam Torbicki, Alec Vahanian, Stephan Windecker, Joao Morais, Carlos Aguiar, Wael Almahmeed, David O. Arnar, Fabio Barili, Kenneth D. Bloch, Ann F. Bolger, Hans Erik Bøtker, Biykem Bozkurt, Raffaele Bugiardini, Christopher Cannon, James de Lemos, Franz R. Eberli, Edgardo Escobar, Mark Hlatky, Stefan James, Karl B. Kern, David J. Moliterno, Christian Mueller, Aleksandar N. Neskovic, Burkert Mathias Pieske, Steven P. Schulman, Robert F. Storey, Kathryn A. Taubert, Pascal Vranckx, Daniel R. Wagner. (2013) Documento de consenso de expertos. Tercera definición universal del infarto de miocardio. Revista Española de Cardiología 66:2, 132.e1-132.e15
22
Oludamilola W. Oluleye, Aaron R. Folsom, Vijay Nambi, Pamela L. Lutsey, Christie M. Ballantyne. (2013) Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Annals of Epidemiology 23:2, 66-73
23
Kelsey Smith, Christopher deFilippi, Tamara Isakova, Orlando M. Gutiérrez, Karen Laliberte, Stephen Seliger, Walter Kelley, Show-Hong Duh, Michael Hise, Robert Christenson, Myles Wolf, James Januzzi. (2013) Fibroblast Growth Factor 23, High-Sensitivity Cardiac Troponin, and Left Ventricular Hypertrophy in CKD. American Journal of Kidney Diseases 61:1, 67-73
24
Matthew J. McQueen, Peter A. Kavsak, Liqin Xu, Olga Shestakovska, Salim Yusuf. (2013) Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. Clinical Biochemistry 46:1-2, 5-9
25
Jordi Ordonez-Llanos, Alessandro Sionis. (2013) Predicting future events in patients with stable cardiovascular disease. Will high-sensitivity cardiac troponins be up to the challenge?. Clinical Biochemistry 46:1-2, 10-11
26
Waleed Ahmed, Christopher L. Schlett, Shanmugam Uthamalingam, Quynh A. Truong, Wolfgang Koenig, Ian S. Rogers, Ron Blankstein, John T. Nagurney, Ahmed Tawakol, James L. Januzzi, Udo Hoffmann. (2013) Single Resting hsTnT Level Predicts Abnormal Myocardial Stress Test in Acute Chest Pain Patients With Normal Initial Standard Troponin. JACC: Cardiovascular Imaging 6:1, 72-82
27
Tobias Reichlin, Raphael Twerenbold, Miriam Reiter, Stephan Steuer, Stefano Bassetti, Cathrin Balmelli, Katrin Winkler, Sabine Kurz, Claudia Stelzig, Michael Freese, Beatrice Drexler, Philip Haaf, Christa Zellweger, Stefan Osswald, Christian Mueller. (2012) Introduction of High-sensitivity Troponin Assays: Impact on Myocardial Infarction Incidence and Prognosis. The American Journal of Medicine 125:12, 1205-1213.e1
28
Ian J. Neeland, Mark H. Drazner, Jarett D. Berry, Colby R. Ayers, Christopher deFilippi, Stephen L. Seliger, Vijay Nambi, Darren K. McGuire, Torbjørn Omland, James A. de Lemos. (2012) Biomarkers of Chronic Cardiac Injury and Hemodynamic Stress Identify a Malignant Phenotype of Left Ventricular Hypertrophy in the General Population. Journal of the American College of Cardiology
29
M. Schueler, M. Vafaie, R. Becker, M. Biener, D. Thomas, M. Mueller, E. Giannitsis, Hugo A. Katus. (2012) Prevalence, kinetic changes and possible reasons of elevated cardiac troponin T in patients with AV nodal re-entrant tachycardia. Acute Cardiac Care 14:4, 131-137
30
Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Maarten L. Simoons, Bernard R. Chaitman, Harvey D. White. (2012) Third Universal Definition of Myocardial Infarction. Global Heart 7:4, 275-295
31
Urban Alehagen, Ulf Dahlström, John Carstensen, Jens F. Rehfeld, Jens P. Goetze. (2012) Combined measurement of copeptin, high-sensitivity troponin T, and N-terminal proBNP improves the identification of patients at risk of cardiovascular death. Cardiovascular Endocrinology 1:4, 68-73
32
L. Kristin Newby, Robert L. Jesse, Joseph D. Babb, Robert H. Christenson, Thomas M. De Fer, George A. Diamond, Francis M. Fesmire, Stephen A. Geraci, Bernard J. Gersh, Greg C. Larsen, Sanjay Kaul, Charles R. McKay, George J. Philippides, William S. Weintraub. (2012) ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations. Journal of the American College of Cardiology 60:23, 2427-2463
33
Gjin Ndrepepa, Siegmund Braun, Lamin King, Martin Hadamitzky, Hans-Ullrich Haase, Katrin Anette Birkmeier, Albert Schömig, Adnan Kastrati. (2012) Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism 61:12, 1780-1786
34
Matthew A. Eisenberg, Israel Green-Hopkins, Mark E. Alexander, Vincent W. Chiang. (2012) Cardiac Troponin T as a Screening Test for Myocarditis in Children. Pediatric Emergency Care 28:11, 1173-1178
35
D. Arroyo, B. Quiroga, N. Panizo, M. Rodríguez-Ferrero, N. Macías, J. Reque, F. Anaya, J. Luño. (2012) High-Sensitivity Troponin T Levels in Kidney Transplant Recipients. Transplantation Proceedings 44:9, 2545-2547
36
Matthias K. Freynhofer, Miloš Tajsić, Johann Wojta, Kurt Huber. (2012) Biomarkers in acute coronary artery disease. Wiener Medizinische Wochenschrift 162:21-22, 489-498
37
Héctor M. García-García, Rohit M. Oemrawsingh, Salvatore Brugaletta, Pascal Vranckx, Jennifer Shannon, Richard Davies, Eric Boersma, Patrick W. Serruys. (2012) Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes. Atherosclerosis 225:1, 142-147
38
Jeanette Normann, Matthias Mueller, Moritz Biener, Mehrshad Vafaie, Hugo A. Katus, Evangelos Giannitsis. (2012) Effect of older age on diagnostic and prognostic performance of high-sensitivity troponin T in patients presenting to an emergency department. American Heart Journal 164:5, 698-705.e4
39
A. Bima, K. Sikaris. (2012) Towards appreciating appropriate clinical responses to highly sensitive cardiac troponin assays. Internal Medicine Journal 42, 16-22
40
Kasper Iversen, Lars Køber, Jens Peter Gøtze, Morten Dalsgaard, Henrik Nielsen, Søren Boesgaard, Morten Bay, Vibeke Kirk, Olav Wendelboe Nielsen. (2012) Troponin T is a strong marker of mortality in hospitalized patients. International Journal of Cardiology
41
Panagiota Pervanidou, Athanassios Akalestos, Despoina Bastaki, Filia Apostolakou, Ioannis Papassotiriou, George Chrousos. (2012) Increased circulating High-Sensitivity Troponin T concentrations in children and adolescents with obesity and the metabolic syndrome: A marker for early cardiac damage?. Metabolism
42
Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Maarten L. Simoons, Bernard R. Chaitman, Harvey D. White, Kristian Thygesen, Joseph S. Alpert, Harvey D. White, Allan S. Jaffe, Hugo A. Katus, Fred S. Apple, Bertil Lindahl, David A. Morrow, Bernard R. Chaitman, Peter M. Clemmensen, Per Johanson, Hanoch Hod, Richard Underwood, Jeroen J. Bax, Robert O. Bonow, Fausto Pinto, Raymond J. Gibbons, Keith A. Fox, Dan Atar, L. Kristin Newby, Marcello Galvani, Christian W. Hamm, Barry F. Uretsky, Ph. Gabriel Steg, William Wijns, Jean-Pierre Bassand, Phillippe Menasche, Jan Ravkilde, E. Magnus Ohman, Elliott M. Antman, Lars C. Wallentin, Paul W. Armstrong, Maarten L. Simoons, James L. Januzzi, Markku S. Nieminen, Mihai Gheorghiade, Gerasimos Filippatos, Russell V. Luepker, Stephen P. Fortmann, Wayne D. Rosamond, Dan Levy, David Wood, Sidney C. Smith, Dayi Hu, Jose-Luis Lopez-Sendon, Rose Marie Robertson, Douglas Weaver, Michal Tendera, Alfred A. Bove, Alexander N. Parkhomenko, Elena J. Vasilieva, Shanti Mendis. (2012) Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology 60:16, 1581-1598
43
J. L. Januzzi, G. Filippatos, M. Nieminen, M. Gheorghiade. (2012) Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. European Heart Journal 33:18, 2265-2271
44
K. Thygesen, J. Mair, E. Giannitsis, C. Mueller, B. Lindahl, S. Blankenberg, K. Huber, M. Plebani, L. M. Biasucci, M. Tubaro, P. Collinson, P. Venge, Y. Hasin, M. Galvani, W. Koenig, C. Hamm, J. S. Alpert, H. Katus, A. S. Jaffe, . (2012) How to use high-sensitivity cardiac troponins in acute cardiac care. European Heart Journal 33:18, 2252-2257
45
Iris P. Garrido, Juan García-Lara, Eduardo Pinar, Francisco Pastor-Pérez, Jesus Sánchez-Mas, Mariano Valdés-Chavarri, Domingo A. Pascual-Figal. (2012) Optical Coherence Tomography and Highly Sensitivity Troponin T for Evaluating Cardiac Allograft Vasculopathy. The American Journal of Cardiology 110:5, 655-661
46
TIMOTHY J PIANTA, ANDREA R HORVATH, VIVIENNE M ELLIS, RINA LEONETTI, CHRISTINE MOFFAT, ELIZABETH A JOSLAND, MARK A BROWN. (2012) Cardiac high-sensitivity troponin T measurement: A layer of complexity in managing haemodialysis patients. Nephrology 17:7, 636-641
47
Luc W. Eurlings, Sandra Sanders-van Wijk, Roland van Kimmenade, Aart Osinski, Lidwien van Helmond, Maud Vallinga, Harry J. Crijns, Marja P. van Dieijen-Visser, Hans-Peter Brunner-La Rocca, Yigal M. Pinto. (2012) Multimarker Strategy for Short-Term Risk Assessment in Patients With Dyspnea in the Emergency Department. Journal of the American College of Cardiology
48
Toru Inami, Yoshihiko Seino, Toshiaki Otsuka, Masanori Yamamoto, Nakahisa Kimata, Daisuke Murakami, Masamichi Takano, Takayoshi Ohba, Chikao Ibuki, Kyoichi Mizuno. (2012) Links between sleep disordered breathing, coronary atherosclerotic burden, and cardiac biomarkers in patients with stable coronary artery disease. Journal of Cardiology 60:3, 180-186
49
Yukihito Sato, Hisayoshi Fujiwara, Yoshiki Takatsu. (2012) Cardiac troponin and heart failure in the era of high-sensitivity assays. Journal of Cardiology 60:3, 160-167
50
N. Assez, C. Lemanski-Brulin, W. Aboukais, Q. Sebilleau, C. Adriansen, F. Rouyer, E. Wiel, P. Goldstein. (2012) Défis de la prise en charge du syndrome coronaire aigu en pré-hospitalier. Archives of Cardiovascular Diseases Supplements 4:3, 223-231
51
Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Maarten L. Simoons, Bernard R. Chaitman, Harvey D. White. (2012) Third universal definition of myocardial infarction. Nature Reviews Cardiology 9:11, 620-633
52
K. Thygesen, J. S. Alpert, A. S. Jaffe, M. L. Simoons, B. R. Chaitman, H. D. White, , , K. Thygesen, J. S. Alpert, H. D. White, , A. S. Jaffe, H. A. Katus, F. S. Apple, B. Lindahl, D. A. Morrow, , B. R. Chaitman, P. M. Clemmensen, P. Johanson, H. Hod, , R. Underwood, J. J. Bax, R. O. Bonow, F. Pinto, R. J. Gibbons, , K. A. Fox, D. Atar, L. K. Newby, M. Galvani, C. W. Hamm, , B. F. Uretsky, P. Gabriel Steg, W. Wijns, J.-P. Bassand, P. Menasche, J. Ravkilde, , E. M. Ohman, E. M. Antman, L. C. Wallentin, P. W. Armstrong, M. L. Simoons, , J. L. Januzzi, M. S. Nieminen, M. Gheorghiade, G. Filippatos, , R. V. Luepker, S. P. Fortmann, W. D. Rosamond, D. Levy, D. Wood, , S. C. Smith, D. Hu, J.-L. Lopez-Sendon, R. M. Robertson, D. Weaver, M. Tendera, A. A. Bove, A. N. Parkhomenko, E. J. Vasilieva, S. Mendis, , J. J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, , J. Morais, C. Aguiar, W. Almahmeed, D. O. Arnar, F. Barili, K. D. Bloch, A. F. Bolger, H. E. Botker, B. Bozkurt, R. Bugiardini, C. Cannon, J. de Lemos, F. R. Eberli, E. Escobar, M. Hlatky, S. James, K. B. Kern, D. J. Moliterno, C. Mueller, A. N. Neskovic, B. M. Pieske, S. P. Schulman, R. F. Storey, K. A. Taubert, P. Vranckx, D. R. Wagner. (2012) Third universal definition of myocardial infarction. European Heart Journal
53
Midori Hasegawa, Junichi Ishii, Fumihiko Kitagawa, Kyoko Kanayama, Hiroshi Takahashi, Yukio Ozaki, Yukio Yuzawa. (2012) Prognostic value of highly sensitive troponin T on cardiac events in patients with chronic kidney disease not on dialysis. Heart and Vessels
54
V. ROLDÁN, F. MARÍN, J. DÍAZ, P. GALLEGO, E. JOVER, M. ROMERA, S. MANZANO-FERNÁNDEZ, T. CASAS, M. VALDÉS, V. VICENTE, G. Y. H. LIP. (2012) High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. Journal of Thrombosis and Haemostasis 10:8, 1500-1507
55
Nathalie Assez, Grégoire Smith, Christophe Adriansen, Wissam Aboukais, Eric Wiel, Patrick Goldstein. (2012) Acute coronary syndromes: is there a place for a real pre-hospital treatment for patients “en route” to the coronary intensive care unit?. EuroIntervention 8:P, P36-P43
56
Jin Zheng, Ping Ye, Leiming Luo, Wenkai Xiao, Ruyi Xu, Hongmei Wu. (2012) Association between blood glucose levels and high-sensitivity cardiac troponin T in an overt cardiovascular disease-free community-based study. Diabetes Research and Clinical Practice 97:1, 139-145
57
Allan S. Jaffe. (2012) Troponin—Past, Present, and Future. Current Problems in Cardiology 37:6, 209-228
58
Francesco Buccelletti, Leonarda Galiuto, Davide Marsiliani, Paolo Iacomini, Pierpaolo Mattogno, Annarita Carroccia, Chiara Cordischi, Simone Antonini, Elisa Fedele, Marta Sabbatini, Nicolò Gentiloni Silveri, Francesco Franceschi. (2012) Comparison of diagnostic accuracy between three different rules of interpreting high sensitivity troponin T results. Internal and Emergency Medicine
59
Ole Geir Solberg, Thor Ueland, Ragnhild Wergeland, Christen P. Dahl, Svend Aakhus, Pål Aukrust, Lars Gullestad. (2012) High-sensitive troponin T and N-terminal-brain-natriuretic-peptide predict outcome in symptomatic aortic stenosis. Scandinavian Cardiovascular Journal1-8
60
Affan Irfan, Raphael Twerenbold, Miriam Reiter, Tobias Reichlin, Claudia Stelzig, Michael Freese, Philip Haaf, Willibald Hochholzer, Stephan Steuer, Stefano Bassetti, Christa Zellweger, Heike Freidank, Federico Peter, Isabel Campodarve, Christophe Meune, Christian Mueller. (2012) Determinants of High-Sensitivity Troponin T Among Patients with a Noncardiac Cause of Chest Pain. The American Journal of Medicine 125:5, 491-498.e1
61
Till Keller, Francisco Ojeda, Tanja Zeller, Philipp S. Wild, Stergios Tzikas, Christoph R. Sinning, Dirk Peetz, Thomas Münzel, Stefan Blankenberg, Karl J. Lackner. (2012) Defining a reference population to determine the 99th percentile of a contemporary sensitive cardiac troponin I assay. International Journal of Cardiology
62
Jan F. Scheitz, Matthias Endres, Hans-Christian Mochmann, Heinrich J. Audebert, Christian H. Nolte. (2012) Frequency, determinants and outcome of elevated troponin in acute ischemic stroke patients. International Journal of Cardiology 157:2, 239-242
63
Christophe Meune, Cathrin Balmelli, Raphael Twerenbold, Miriam Reiter, Tobias Reichlin, Ronny Ziller, Beatrice Drexler, Claudia Stelzig, Michael Freese, Claudia Wolf, Philip Haaf, Stefan Osswald, Christian Mueller. (2012) Utility of 14 novel biomarkers in patients with acute chest pain and undetectable levels of conventional cardiac troponin. International Journal of Cardiology
64
Razvan T. Dadu, Vijay Nambi, Christie M. Ballantyne. (2012) Developing and assessing cardiovascular biomarkers. Translational Research 159:4, 265-276
65
Devin W. Kehl, Navaid Iqbal, Arrash Fard, Ben A. Kipper, Alejandro De La Parra Landa, Alan S. Maisel. (2012) Biomarkers in acute myocardial injury. Translational Research 159:4, 252-264
66
Harvey D White. Biomarkers in acute coronary syndromes. In: Advances in Acute Coronary Syndrome Management. Future Medicine Ltd, 2012:18-29.
67
T. Omland. (2012) Sensitive cardiac troponin assays: sense and sensibility. European Heart Journal
68
J. George, D. Jack, G. Mackle, T. S. Callaghan, L. Wei, C. C. Lang, E. Dow, A. D. Struthers. (2012) High sensitivity troponin T provides useful prognostic information in non-acute chest pain. QJM 105:2, 159-166
69
Christian W. Hamm, Jean-Pierre Bassand, Stefan Agewall, Jeroen Bax, Eric Boersma, Hector Bueno, Pio Caso, Dariusz Dudek, Stephan Gielen, Kurt Huber, Magnus Ohman, Mark C. Petrie, Frank Sonntag, Miguel Sousa Uva, Robert F. Storey, William Wijns, Doron Zahger. (2012) Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología 65:2, 173.e1-173.e55
70
Christian Stratz, Michael Amann, David D. Berg, David A. Morrow, Franz-Josef Neumann, Willibald Hochholzer. (2012) Novel biomarkers in cardiovascular disease. Cardiology in Review1
71
B. M. Biccard. (2012) Surgery and cardiovascular outcomes: an untapped public health benefit that potentially saves lives. Anaesthesia 67:2, 106-109
72
R. Twerenbold, A. Jaffe, T. Reichlin, M. Reiter, C. Mueller. (2012) High-sensitive troponin T measurements: what do we gain and what are the challenges?. European Heart Journal
73
Ragnhild Røysland, Gunnhild Kravdal, Arne Didrik Høiseth, Ståle Nygård, Pirouz Badr, Tor-Arne Hagve, Torbjorn Omland, Helge Røsjø. (2012) Cardiac troponin T levels and exercise stress testing in patients with suspected coronary artery disease – the Akershus Cardiac Examination (ACE) 1 study. Clinical Science
74
Jonathan Rubin, Kunihiro Matsushita, Christie M. Ballantyne, Ron Hoogeveen, Josef Coresh, Elizabeth Selvin. (2012) Chronic Hyperglycemia and Subclinical Myocardial Injury. Journal of the American College of Cardiology 59:5, 484-489
75
James A. de Lemos, Scott M. Grundy. (2012) Low Levels of Circulating Troponin as an Intermediate Phenotype in the Pathway to Heart Failure. Journal of the American College of Cardiology 59:5, 490-492
76
Samuel D. Vasikaran, Abdulhadi Bima, Mona Botros, Kenneth A. Sikaris. (2012) Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assays—an update from the Canadian society of clinical chemists (CSCC); the case for age related acute myocardial infarction (AMI) cut-offs. Clinical Biochemistry
77
John T. Wilkins, Donald M. Lloyd-Jones. (2012) Are Novel Serum Biomarkers Informative?. Medical Clinics of North America 96:1, 1-11
78
David A. Morrow, William E. Boden. Stable Ischemic Heart Disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, 2012:1210-1269.
79
Diana Hernández-Romero, José María García-Salas, Ángel López-Cuenca, Patricio Pérez-Berbel, Carmen Puche, Teresa Casas, Esteban Orenes-Piñero, Sergio Manzano-Fernández, Mariano Valdés, Francisco Marín. (2012) High-Sensitivity Troponin T and Copeptin in Non-ST Acute Coronary Syndromes: Implications for Prognosis and Role of hsTnT and Copeptin in Non-STEACS. The Scientific World Journal 2012, 1-8
80
J.K. Jensen, T. Ueland, P. Aukrust, L. Antonsen, S.R. Kristensen, J.L. Januzzi, J. Ravkilde. (2012) Highly Sensitive Troponin T in Patients with Acute Ischemic Stroke. European Neurology 68:5, 287-293
81
Arne Høiseth, Torbjørn Omland, Tor-Arne Hagve, Pål H Brekke, Vidar Søyseth. (2012) NT-proBNP independently predicts long term mortality after acute exacerbation of COPD – a prospective cohort study. Respiratory Research 13:1, 97
82
Christophe Meune, Cathrin Balmelli, Raphael Twerenbold, Tobias Reichlin, Miriam Reiter, Philip Haaf, Stephan Steuer, Stefano Bassetti, Konstantin Sakarikos, Isabel Campodarve, Christa Zellweger, Affan Irfan, Beatrice Drexler, Christian Mueller. (2011) Patients with Acute Coronary Syndrome and Normal High-sensitivity Troponin. The American Journal of Medicine 124:12, 1151-1157
83
, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M. C. Petrie, F. Sonntag, M. S. Uva, R. F. Storey, W. Wijns, D. Zahger, , J. J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, , S. Windecker, S. Achenbach, L. Badimon, M. Bertrand, H. E. Botker, J.-P. Collet, F. Crea, N. Danchin, E. Falk, J. Goudevenos, D. Gulba, R. Hambrecht, J. Herrmann, A. Kastrati, K. Kjeldsen, S. D. Kristensen, P. Lancellotti, J. Mehilli, B. Merkely, G. Montalescot, F.-J. Neumann, L. Neyses, J. Perk, M. Roffi, F. Romeo, M. Ruda, E. Swahn, M. Valgimigli, C. J. Vrints, P. Widimsky. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 32:23, 2999-3054
84
Christophe Meune, Cathrin Balmelli, Tanja Marxer, Julia Meissner, Raphael Twerenbold, Miriam Reiter, Tobias Reichlin, Philip Haaf, Beatrice Drexler, Affan Irfan, Claudia Stelzig, Michael Freese, Katrin Winkler, Christian Mueller. (2011) High-sensitive Troponin, B-type natriuretic peptide and coronary angiogram findings in patients with non ST-segment elevation acute coronary syndrome. International Journal of Cardiology 153:3, 335-337
85
Kai M. Eggers, Per Venge. (2011) Utility of B-type natriuretic peptides and cardiac troponins for population screening regarding cardiac abnormalities. Pathology1
86
Carmen Muñoz-Esparza, Iris P. Garrido, Rosa Blanco, Teresa Casas, Cristina González-Cánovas, Francisco Pastor-Pérez, Pablo Peñafiel, Alfredo Minguela, Mariano Valdés, Domingo A. Pascual-Figal. (2011) Utilidad de la prueba de troponina T de alta sensibilidad en la detección de rechazo agudo en trasplante cardiaco. Revista Española de Cardiología 64:12, 1109-1113
87
Carmen Muñoz-Esparza, Iris P. Garrido, Rosa Blanco, Teresa Casas, Cristina González-Cánovas, Francisco Pastor-Pérez, Pablo Peñafiel, Alfredo Minguela, Mariano Valdés, Domingo A. Pascual-Figal. (2011) Usefulness of High Sensitivity Troponin T Assay in Detecting Acute Allograft Rejection After Heart Transplantation. Revista Española de Cardiología (English Edition) 64:12, 1109-1113
88
Carsten G. Jungbauer, Julia Riedlinger, Stefan Buchner, Christoph Birner, Markus Resch, Matthias Lubnow, Kurt Debl, Monika Buesing, Hendrik Huedig, Günter Riegger, Andreas Luchner. (2011) High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-terminal pro-b-type natriuretic peptide. Clinical Chemistry and Laboratory Medicine 49:11, 1899-1906
89
Peter A. Kavsak, Lynn C. Allen, Fred S. Apple, Ronald A. Booth, Pak-Cheung Chan, Edgard Delvin, Albert Fraser, Lei Fu, Douglas Gornall, Christine Collier, Stephen Hill, Barry Hoffman, Yun Huang, Joël Lavoie, Amy Lou, Andre Mattman, Matthew McQueen, Qing H. Meng, Curtis Oleschuk, Morris Pudek, Edward Randell, Kun-Young Sohn, Laurel Thorlacius, Paul M. Yip, Nagib Dahdah, P.J. Devereaux, Sukhbinder Dhesy-Thind, Sebastien J. Hotte, Andrew Worster. (2011) Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assays—An update from the Canadian society of clinical chemists (CSCC). Clinical Biochemistry 44:16, 1273-1277
90
M. Reiter, R. Twerenbold, T. Reichlin, B. Benz, P. Haaf, J. Meissner, W. Hochholzer, C. Stelzig, M. Freese, C. Heinisch, C. Balmelli, B. Drexler, H. Freidank, K. Winkler, I. Campodarve, J. Gea, C. Mueller. (2011) Early diagnosis of acute myocardial infarction in patients with pre-existing coronary artery disease using more sensitive cardiac troponin assays. European Heart Journal
91
N. Assez, E. Wiel, C. Lemanski-Brulin, C. Adriansen, P. Goldstein. (2011) Syndromes coronariens aigus : prise en charge thérapeutique en urgence. Annales françaises de médecine d'urgence
92
Yuan-Cheng Chen, Wan-Wen Cao, Yuan Cao, Lin Zhang, Bo-bo Chang, Wen-Liang Yang, Xiao-Quan Liu. (2011) Using neural networks to determine the contribution of danshensu to its multiple cardiovascular activities in acute myocardial infarction rats. Journal of Ethnopharmacology 138:1, 126-134
93
Chiho Kawahara, Takayoshi Tsutamoto, Hiroshi Sakai, Keizo Nishiyama, Masayuki Yamaji, Masanori Fujii, Takashi Yamamoto, Minoru Horie. (2011) Prognostic value of serial measurements of highly sensitive cardiac troponin I in stable outpatients with nonischemic chronic heart failure. American Heart Journal 162:4, 639-645
94
Gjin Ndrepepa, Siegmund Braun, Stefanie Schulz, Massimiliano Fusaro, Dritan Keta, Jürgen Pache, Melchior Seyfarth, Julinda Mehilli, Albert Schömig, Adnan Kastrati. (2011) Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. European Journal of Clinical Investigation 41:10, 1054-1062
95
Nikolaos Markou, Leonidas Gregorakos, Pavlos Myrianthefs. (2011) Increased blood troponin levels in ICU patients. Current Opinion in Critical Care 17:5, 454-463
96
Yongyi Bai, Ping Ye, Leiming Luo, Wenkai Xiao, Ruyi Xu, Hongmei Wu, Jie Bai. (2011) Arterial stiffness is associated with minimally elevated high-sensitivity cardiac, troponin T levels in a community-dwelling population. Atherosclerosis 218:2, 493-498
97
Michael Christ, Thomas Bertsch, Steffen Popp, Philipp Bahrmann, Hans-Jürgen Heppner, Christian Müller. (2011) High-sensitivity troponin assays in the evaluation of patients with acute chest pain in the emergency department. Clinical Chemistry and Laboratory Medicine---
98
Gjin Ndrepepa, Siegmund Braun, Stefanie Schulz, Julinda Mehilli, Albert Schömig, Adnan Kastrati. (2011) High-Sensitivity Troponin T Level and Angiographic Severity of Coronary Artery Disease. The American Journal of Cardiology 108:5, 639-643
99
Peter A. Kavsak, Mike Walsh, Sadeesh Srinathan, Laurel Thorlacius, Giovanna Lurati Buse, Fernando Botto, Shirley Pettit, Matthew J. McQueen, Stephen A. Hill, Sabu Thomas, Marko Mrkobrada, Pablo Alonso-Coello, Otavio Berwanger, Bruce M. Biccard, George Cembrowski, Matthew T.V. Chan, Clara K. Chow, Angeles de Miguel, Mercedes Garcia, Michelle M. Graham, Michael J. Jacka, J.H. Kueh, Stephen C.H. Li, Lydia C.W. Lit, Cecília Martínez-Brú, Prebashini Naidoo, Peter Nagele, Rupert M. Pearse, Reitze N. Rodseth, Daniel I. Sessler, Alben Sigamani, Wojciech Szczeklik, Maria Tiboni, Juan Carlos Villar, C.Y. Wang, Denis Xavier, P.J. Devereaux. (2011) High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: A prospective cohort study. Clinical Biochemistry 44:12, 1021-1024
100
Paul F. Kantor, Paolo Rusconi, Steven Lipshultz, Seema Mital, James D. Wilkinson, Michael Burch. (2011) Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure: Summary from the Second International Conference on Pediatric Cardiomyopathy. Progress in Pediatric Cardiology 32:1, 11-14
101
Javier Sanz, Valentin Fuster. (2011) The Year in Atherothrombosis. Journal of the American College of Cardiology 58:8, 779-791
102
Amy B. Stancoven, Angela B. Shiue, Amit Khera, Kristi Pinkston, Ibrahim A. Hashim, Andrew Wang, James A. de Lemos, Gail E. Peterson. (2011) Association of Troponin T, Detected With Highly Sensitive Assay, and Outcomes in Infective Endocarditis. The American Journal of Cardiology 108:3, 416-420
103
Kai M. Eggers, Magnus Nygren, Per Venge, Tomas Jernberg, Bernt G. Wikström. (2011) High-sensitive troponin T and I are related to invasive hemodynamic data and mortality in patients with left-ventricular dysfunction and precapillary pulmonary hypertension. Clinica Chimica Acta 412:17-18, 1582-1588
104
I. Tentzeris, R. Jarai, S. Farhan, T. Perkmann, M. A. Schwarz, G. Jakl, J. Wojta, K. Huber. (2011) Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. European Journal of Heart Failure 13:7, 726-733
105
Peter A. Kavsak. (2011) Early standardization of high sensitivity troponin T reporting - a lost opportunity. Clinical Biochemistry 44:10-11, 758-759
106
Helge Røsjø, Johanna Andreassen, Thor Edvardsen, Torbjørn Omland. (2011) Prognostic Usefulness of Circulating High-Sensitivity Troponin T in Aortic Stenosis and Relation to Echocardiographic Indexes of Cardiac Function and Anatomy. The American Journal of Cardiology 108:1, 88-91
107
I. Ramasamy. (2011) Biochemical markers in acute coronary syndrome. Clinica Chimica Acta 412:15-16, 1279-1296
108
Gjin Ndrepepa, Siegmund Braun, Stefanie Schulz, Robert A. Byrne, Jürgen Pache, Julinda Mehilli, Albert Schömig, Adnan Kastrati. (2011) Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. Clinica Chimica Acta 412:15-16, 1350-1356
109
France Boyaud, Nicolas Inguimbert. (2011) Soluble fms-like tyrosine kinase-1 antibody for diagnosis purposes (WO2010075475). Expert Opinion on Therapeutic Patents 21:6, 971-975
110
Aslan T. Turer, Tayo A. Addo, Justin L. Martin, Marc S. Sabatine, Gregory D. Lewis, Robert E. Gerszten, Ellen C. Keeley, Joaquin E. Cigarroa, Richard A. Lange, L. David Hillis, James A. de Lemos. (2011) Myocardial Ischemia Induced by Rapid Atrial Pacing Causes Troponin T Release Detectable by a Highly Sensitive Assay. Journal of the American College of Cardiology 57:24, 2398-2405
111
Harvey D. White. (2011) Pathobiology of Troponin Elevations
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 57:24, 2406-2408
112
Boris T. Ivandic, Eberhard Spanuth, Marcus Kleber, Tanja B. Grammer, Winfried März. (2011) High-sensitivity troponin T improves the prognostic value of N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: results from the LURIC Study. Clinical Chemistry and Laboratory Medicine 49:6, 1053-1058
113
M. Reiter, R. Twerenbold, T. Reichlin, P. Haaf, F. Peter, J. Meissner, W. Hochholzer, C. Stelzig, M. Freese, C. Heinisch, T. Breidthardt, H. Freidank, K. Winkler, I. Campodarve, J. Gea, C. Mueller. (2011) Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. European Heart Journal 32:11, 1379-1389
114
Marit Aarones, Lars Gullestad, Svend Aakhus, Thor Ueland, Rita Skaardal, Halfdan Aass, Ragnhild Wergeland, Hans-Jørgen Smith, Pål Aukrust, Erik Kongsgaard. (2011) Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled for cardiac resynchronization therapy. American Heart Journal 161:6, 1031-1037
115
HG Laverty, C Benson, EJ Cartwright, MJ Cross, C Garland, T Hammond, C Holloway, N McMahon, J Milligan, BK Park, M Pirmohamed, C Pollard, J Radford, N Roome, P Sager, S Singh, T Suter, W Suter, A Trafford, PGA Volders, R Wallis, R Weaver, M York, JP Valentin. (2011) How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. British Journal of Pharmacology 163:4, 675-693
116
Ruyi Xu, Ping Ye, Leiming Luo, Wenkai Xiao, Li Sheng, Hongmei Wu, Jie Bai, Zhennan Dong, Xinxin Deng. (2011) Association between high-sensitivity cardiac troponin T and predicted cardiovascular risks in a community-based population. International Journal of Cardiology 149:2, 253-256
117
Olaf Schulz, Markus Reinicke, Jochen Krämer, Gunnar Berghöfer, Ricarda Bensch, Ingolf Schimke, Allan Jaffe. (2011) Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease: Use of a new monoclonal antibody-based assay. Clinica Chimica Acta 412:11-12, 880-886
118
Maria Hughes, Frank Kee, Veikko Salomaa. (2011) Clinical Utility of Multiple Biomarker Panels for Cardiovascular Disease Risk Prediction. Current Cardiovascular Risk Reports 5:2, 165-173
119
A.K. Saenger, R. Beyrau, S. Braun, R. Cooray, A. Dolci, H. Freidank, E. Giannitsis, S. Gustafson, B. Handy, H. Katus, S.E. Melanson, M. Panteghini, P. Venge, M. Zorn, P. Jarolim, D. Bruton, J. Jarausch, A.S. Jaffe. (2011) Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clinica Chimica Acta 412:9-10, 748-754
120
Exadaktylos Aristomenis, Sauter Thomas, Zimmermann Heinz, Schnüriger Beat, Buhl Daniela. (2011) Highly Sensitive Cardiac Troponin in Blunt Chest Trauma: After the Gathering Comes the Scattering?. The Journal of Trauma: Injury, Infection, and Critical Care 70:3, 766-767
121
Alex Blatt, Gil Moravsky, Semion Pilipodi, Anat Mor, Patricia Benbeniste, Zvi Vered, Sa’ar Minha. (2011) Can Dobutamine Stress Echocardiography Induce Cardiac Troponin Elevation?. Echocardiography 28:2, 219-222
122
John M. Murkin. (2011) Cerebral Oximetry. Anesthesiology 114:1, 12-13
123
Matthias Heringlake, Christof Garbers, Jan-Hendrik Käbler, Ingrid Anderson, Hermann Heinze, Julika Schön, Klaus-Ulrich Berger, Leif Dibbelt, Hans-Hinrich Sievers, Thorsten Hanke. (2011) Preoperative Cerebral Oxygen Saturation and Clinical Outcomes in Cardiac Surgery. Anesthesiology 114:1, 58-69
124
Koichi Setsuta, Yasuyuki Kitahara, Masato Arae, Taminori Ohbayashi, Yoshihiko Seino, Kyoichi Mizuno. (2011) Elevated Cardiac Troponin T Predicts Adverse Outcomes in Hypertensive Patients. International Heart Journal 52:3, 164-169
125
, Helge Røsjø, Marjut Varpula, Tor-Arne Hagve, Sari Karlsson, Esko Ruokonen, Ville Pettilä, Torbjørn Omland. (2011) Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intensive Care Medicine 37:1, 77-85
126
Junnichi Ishii. (2011) Application of High-Sensitivity Cardiac Troponin Values. Circulation Journal 75:12, 2753-2754
127
Chiho Kawahara, Takayoshi Tsutamoto, Keizo Nishiyama, Masayuki Yamaji, Hiroshi Sakai, Masanori Fujii, Takashi Yamamoto, Minoru Horie. (2011) Prognostic Role of High-Sensitivity Cardiac Troponin T in Patients With Nonischemic Dilated Cardiomyopathy. Circulation Journal 75:3, 656-661
128
José A. Barrabés, Vicente Bodí, Javier Jiménez-Candil, Antonio Fernández-Ortiz. (2011) Actualización en cardiopatía isquémica. Revista Española de Cardiología 64, 50-58
129
M.G. Bissell. (2011) A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery Disease. Yearbook of Pathology and Laboratory Medicine 2011, 259-260
130
Gjin Ndrepepa, Siegmund Braun, Julinda Mehilli, K. Anette Birkmeier, Robert A. Byrne, Ilka Ott, Karin Hösl, Stefanie Schulz, Massimiliano Fusaro, Jürgen Pache, Jörg Hausleiter, Karl-Ludwig Laugwitz, Steffen Massberg, Melchior Seyfarth, Albert Schömig, Adnan Kastrati. (2011) Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. American Heart Journal 161:1, 68-75
131
Pierre Théroux. Treatment Principles and Emerging Therapies in Acute Coronary Syndromes without ST-Segment Elevation. In: Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease. Elsevier, 2011:194-200.
132
T.A. Winkel, O. Schouten, S.E. Hoeks, M.T. Voûte, M. Chonchol, D. Goei, W.-J. Flu, J.-P. van Kuijk, J. Lindemans, H.J.M. Verhagen, J.J. Bax, D. Poldermans. (2010) Prognosis of Vascular Surgery Patients Using a Quantitative Assessment of Troponin T Release: Is the Crystal Ball still Clear?. European Journal of Vascular and Endovascular Surgery 40:6, 739-746
133
Michael Christ, Steffen Popp, Hella Pohlmann, Michail Poravas, Dina Umarov, Ruth Bach, Thomas Bertsch. (2010) Implementation of High Sensitivity Cardiac Troponin T Measurement in the Emergency Department. The American Journal of Medicine 123:12, 1134-1142
134
Jonas Hallén, Dan Atar. (2010) A window into your heart: taking cardiac troponin to the next level. Biomarkers in Medicine 4:6, 889-894
135
Peter A. Kavsak, Matthew J. McQueen. (2010) Sensitive and high sensitivity cardiac troponin I concentrations in the Heart Outcomes Prevention Evaluation (HOPE) study — A high risk population. Clinica Chimica Acta 411:21-22, 1832
136
Marie Fertin, Bernadette Hennache, Martial Hamon, Pierre V. Ennezat, Frédéric Biausque, Mariam Elkohen, Olivier Nugue, Olivier Tricot, Nicolas Lamblin, Florence Pinet, Christophe Bauters. (2010) Usefulness of Serial Assessment of B-Type Natriuretic Peptide, Troponin I, and C-Reactive Protein to Predict Left Ventricular Remodeling After Acute Myocardial Infarction (from the REVE-2 Study). The American Journal of Cardiology 106:10, 1410-1416
137
A. V. Kristen, E. Giannitsis, S. Lehrke, U. Hegenbart, M. Konstandin, D. Lindenmaier, C. Merkle, S. Hardt, P. A. Schnabel, C. Rocken, S. O. Schonland, A. D. Ho, T. J. Dengler, H. A. Katus. (2010) Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 116:14, 2455-2461
138
Jochen Jarausch. (2010) Diagnostic and Prognostic Information Provided by a High Sensitivity Assay for Cardiac Troponin T. Journal of Medical Biochemistry 29:4, 274-281
139
M. Siervo, D. Ruggiero, R. Sorice, T. Nutile, M. Aversano, B. C. M. Stephan, M. Ciullo. (2010) Angiogenesis and biomarkers of cardiovascular risk in adults with metabolic syndrome. Journal of Internal Medicine 268:4, 338-347
140
T. Omland. (2010) New features of troponin testing in different clinical settings. Journal of Internal Medicine 268:3, 207-217
141
Jonathan R. Enriquez, James A. De Lemos. (2010) Should We Focus on Novel Risk Markers and Screening Tests to Better Predict and Prevent Cardiovascular Disease?. Preventive Cardiology 13:4, 152-159
142
Peter A. Kavsak, Matthew J. McQueen. (2010) High sensitivity cardiac troponin concentration cutoffs—is a healthy population the right reference population for those with underlying cardiac disease?. Clinical Biochemistry 43:13-14, 1037-1038
143
M. Lankeit, D. Friesen, J. Aschoff, C. Dellas, G. Hasenfuss, H. Katus, S. Konstantinides, E. Giannitsis. (2010) Highly sensitive troponin T assay in normotensive patients with acute pulmonary embolism. European Heart Journal 31:15, 1836-1844
144
Allan S. Jaffe, Jordi Ordonez-Llanos. (2010) Troponinas ultrasensibles en el dolor torácico y los síndromes coronarios agudos. ¿Un paso hacia delante?. Revista Española de Cardiología 63:7, 763-769
145
Arthur Filusch, Evangelos Giannitsis, Hugo A. Katus, Franz J. Meyer. (2010) High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. Clinical Science 119:5, 207-213
146
Geoffrey de Couto, Maral Ouzounian, Peter P. Liu. (2010) Early detection of myocardial dysfunction and heart failure. Nature Reviews Cardiology 7:6, 334-344
147
Toshiaki Otsuka, Tomoyuki Kawada, Chikao Ibuki, Yoshihiko Seino. (2010) Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease. American Heart Journal 159:6, 972-978
148
Harvey D. White. (2010) Higher sensitivity troponin levels in the community: What do they mean and how will the diagnosis of myocardial infarction be made?. American Heart Journal 159:6, 933-936
149
Olaf Schulz, Markus Reinicke, Gunnar H. Berghoefer, Ricarda Bensch, Jochen Kraemer, Ingolf Schimke, Allan S. Jaffe. (2010) High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease: An initial foray. Clinica Chimica Acta 411:11-12, 812-817
150
Olivier Muller, Emanuele Barbato, Bernard De Bruyne, Jozef Bartunek. (2010) Biomarkers of vulnerable plaque: the missing link with ischemia. Biomarkers in Medicine 4:3, 375-383
151
Raphael Twerenbold, Tobias Reichlin, Christian Mueller. (2010) Clinical application of sensitive cardiac troponin assays: potential and limitations. Biomarkers in Medicine 4:3, 395-401
152
(2010) Sensitive Cardiac Troponin T Assay. New England Journal of Medicine 362:13, 1242-1243
Free Full Text153
Peter A. Kavsak, Andrew Worster, John J. You, Mark Oremus, Adell Elsharif, Stephen A. Hill, P.J. Devereaux, Andrew R. MacRae, Allan S. Jaffe. (2010) Identification of myocardial injury in the emergency setting. Clinical Biochemistry 43:6, 539-544
154
(2010) Myocardial infarction redefined: the impact of high-sensitivity troponin testing on clinical practice. Internal Medicine Journal 40:3, 171-172
155
Serge Masson, Roberto Latini, Inder S. Anand. (2010) An Update on Cardiac Troponins as Circulating Biomarkers in Heart Failure. Current Heart Failure Reports 7:1, 15-21
156
Bryony M. Mearns. (2010) Coronary artery disease: New troponin T test allows prediction of CV events in patients with stable CAD. Nature Reviews Cardiology 7:3, 120-120
- Letters
